Edition:
United Kingdom

Bellerophon Therapeutics Inc (BLPH.OQ)

BLPH.OQ on NASDAQ Stock Exchange Global Market

0.59USD
23 May 2019
Change (% chg)

-- (--)
Prev Close
$0.59
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
71,279
52-wk High
$3.30
52-wk Low
$0.47

Latest Key Developments (Source: Significant Developments)

Bellerophon Therapeutics Q1 Loss Per Share $0.01
Thursday, 9 May 2019 

May 9 (Reuters) - Bellerophon Therapeutics Inc ::BELLEROPHON PROVIDES BUSINESS UPDATE AND REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.01.AS OF MARCH 31, 2019, COMPANY HAD CASH AND CASH EQUIVALENTS OF $20.7 MILLION, COMPARED TO $16.6 MILLION AT DECEMBER 31, 2018.  Full Article

Bellerophon Therapeutics Reports Q4 Loss Per Share Of $0.02
Thursday, 14 Mar 2019 

March 14 (Reuters) - Bellerophon Therapeutics Inc ::BELLEROPHON PROVIDES BUSINESS UPDATE AND REPORTS FOURTH QUARTER AND FULL-YEAR 2018 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.02.AS OF DECEMBER 31, 2018, HAD CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $16.6 MILLION.  Full Article

Bellerophon Therapeutics - Public Offering Of 10 Million Common Shares Priced At $0.70 Per Share
Wednesday, 23 Jan 2019 

Jan 23 (Reuters) - Bellerophon Therapeutics Inc ::BELLEROPHON ANNOUNCES PRICING OF $7 MILLION PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 10.0 MILLION COMMON SHARES PRICED AT $0.70PER SHARE.  Full Article

Bellerophon Therapeutics Inc Announces Proposed Public Offering Of Common Stock
Tuesday, 22 Jan 2019 

Jan 22 (Reuters) - Bellerophon Therapeutics Inc ::BELLEROPHON THERAPEUTICS, INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.BELLEROPHON THERAPEUTICS INC - BELLEROPHON INTENDS TO USE NET PROCEEDS FROM THIS OFFERING TO FUND WORKING CAPITAL.  Full Article

Bellerophon Therapeutics Q1 Shr Loss $0.04
Thursday, 10 May 2018 

May 10 (Reuters) - Bellerophon Therapeutics Inc ::BELLEROPHON PROVIDES BUSINESS UPDATE AND REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.BELLEROPHON THERAPEUTICS Q1 BASIC EARNINGS PER SHARE $0.07 .BELLEROPHON THERAPEUTICS INC - QTRLY LOSS PER SHARE $0.04.  Full Article

Bellerophon Reaches Agreement With FDA On Study Design Of Phase 2b Trial Of INOpulse
Tuesday, 8 May 2018 

May 8 (Reuters) - Bellerophon Therapeutics Inc ::BELLEROPHON REACHES AGREEMENT WITH FDA ON STUDY DESIGN OF PHASE 2B TRIAL OF INOPULSE® FOR TREATMENT OF PULMONARY HYPERTENSION ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE.BELLEROPHON REACHES AGREEMENT WITH FDA ON STUDY DESIGN OF PHASE 2B TRIAL OF INOPULSE® FOR TREATMENT OF PULMONARY HYPERTENSION ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE.BELLEROPHON THERAPEUTICS - PHASE 2B STUDY TO BE A DOUBLE-BLIND, PLACEBO-CONTROLLED, CLINICAL TRIAL IN ABOUT 90 PH-COPD PATIENTS.BELLEROPHON THERAPEUTICS - PRIMARY END POINT OF STUDY WILL BE SIX-MINUTE WALKING DISTANCE, STUDY TO ALSO ASSESS MULTIPLE SECONDARY ENDPOINTS.  Full Article

Bellerophon Therapeutics reports Q3 loss per share $0.22
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Bellerophon Therapeutics Inc :Bellerophon provides business update and reports third quarter 2017 financial results.Q3 loss per share $0.22.Says ‍ phase 2a study for inopulse met its primary endpoint​.  Full Article

Bellerophon Therapeutics says selling stockholders may offer, resell up to 38.9 mln shares - SEC filing
Tuesday, 24 Oct 2017 

Oct 24 (Reuters) - Bellerophon Therapeutics Inc :Bellerophon Therapeutics Inc files to say selling stockholders may offer and resell up to 38.9 million shares of co's common stock - SEC filing.Bellerophon Therapeutics Inc - the selling stockholders will receive all of the proceeds from any sales of the shares offered.  Full Article

Bellerophon announces $23 million private placement
Wednesday, 27 Sep 2017 

Sept 27 (Reuters) - Bellerophon Therapeutics Inc :Bellerophon announces $23 million private placement.Bellerophon Therapeutics Inc - ‍financing was led by Puissance Capital Management and Venrock Healthcare Capital Partners​.Bellerophon Therapeutics Inc - will sell about 19.4 million shares of stock, warrants to purchase about 19.4 million shares of stock for about $23.4 million.  Full Article

Bellerophon announces positive top line Phase 2 data of INOpulse
Tuesday, 5 Sep 2017 

Sept 5 (Reuters) - Bellerophon Therapeutics Inc :Bellerophon announces positive top line Phase 2 data of INOpulse for treatment of Pulmonary Hypertension associated with Chronic Obstructive Pulmonary Disease.Bellerophon Therapeutics Inc - ‍acute results showed a statistically significant increase in blood vessel volume on INO compared to baseline​.Bellerophon Therapeutics Inc - ‍study therapy was well tolerated with no related safety concerns​.Bellerophon Therapeutics Inc - ‍is currently conducting a Phase 3 trial for INOpulse for treatment of Pulmonary Arterial Hypertension​.Bellerophon Therapeutics Inc - ‍top-line data for Phase 3 trial of INOpulse expected in 2018​.  Full Article